ÿþ<HTML><HEAD><TITLE>25º Congresso Brasileiro de Microbiologia </TITLE><link rel=STYLESHEET type=text/css href=css.css></HEAD><BODY aLink=#ff0000 bgColor=#FFFFFF leftMargin=0 link=#000000 text=#000000 topMargin=0 vLink=#000000 marginheight=0 marginwidth=0><table align=center width=700 cellpadding=0 cellspacing=0><tr><td align=left bgcolor=#cccccc valign=top width=550><font face=arial size=2><strong><font face=Verdana, Arial, Helvetica, sans-serif size=3><font size=1>25º Congresso Brasileiro de Microbiologia </font></font></strong><font face=Verdana size=1><b><br></b></font><font face=Verdana, Arial,Helvetica, sans-serif size=1><strong> </strong></font></font></td><td align=right bgcolor=#cccccc valign=top width=150><font face=arial size=2><strong><font face=Verdana, Arial, Helvetica, sans-serif size=1><font  size=1>ResumoID:390-1</font></em></font></strong></font></td></tr><tr><td colspan=2><br><br><table align=center width=700><tr><td>Área: <b>Micobacteriologa ( Divisão C )</b><p align=justify><strong>
RESEARCH OF NEW MIXED-CHELATE COPPER COMPLEXES WITH QUINOXALINE AND ALANINE AS LIGANDS, POTENTIAL ANTIMYCOBACTERIAL AGENTS    
</strong></p><p align=justify><b>Fernando Rogério Pavan </b>  (<i>UNESP</i>); <b><u>Miriane Cristina  Faradezo </u></b>  (<i>UNIMED</i>); <b>Antonio J.  Costa-filho </b>  (<i>USP</i>); <b>Ernanni D.  Vieira </b>  (<i>USP</i>); <b>Antonio  Monge </b>  (<i>CIFA</i>); <b>Graciela  Borthagaray </b>  (<i>UDELAR</i>); <b>Dinorah  Gambino </b>  (<i>UDELAR</i>); <b>María H.  Torre </b>  (<i>UDELAR</i>); <b>Clarice Queico Fujimura  Leite </b>  (<i>UNESP</i>)<br><br></p><b><font size=2>Resumo</font></b><p align=justify class=tres><font size=2>
  <div style="text-align: justify;"><span style="font-weight: bold;">Introduction:</span> Tuberculosis is an infectious disease caused by mycobacteria, mainly <span style="font-style: italic;">Mycobacterium tuberculosis</span>. It can lead to serious complications and even death, especially if it is accompanied by other bacterial infections and if the patients have their immune systems compromised by immunosuppressive drugs, abuse substances, or HIV/AIDS, among others. The World Health Organization (WHO) estimates that about 30 million people will be infected in the next 20 years, not only in the third world but also in the developed countries. In view of the importance of this disease and the emergence of multi-drug-resistant (MDR) strains, the investigation an development of new drugs is a leading area of research. The study of quinoxaline derivatives has become of much interest in recent years due to their antibacterial, antiviral, anticancer, antifungal, antihelminthes and insecticidal activities. <span style="font-weight: bold;">Objetives: </span>The present work describes the anti-<span style="font-style: italic;">M. tuberculosis</span> activities of a new series of mixed-chelate Cu(II) complexes with different non- and mono-substituted 3-aminoquinoxaline-2-carbonitrile <span style="font-style: italic;">N1</span>,<span style="font-style: italic;">N4</span>-dioxide derivatives and alanine (ala) as ligands. <span style="font-weight: bold;">Material and Methods:</span> The MIC (Minimum Inhibitory Concentration) of three new complexes were investigated in order to determine their in vitro antimycobacterial activity against <span style="font-style: italic;">M. tuberculosis</span> H<sub>37</sub>Rv (ATCC 27294). The MIC values were determined using the MABA method (Microplate Alamar Blue Assay). <span style="font-weight: bold;">Results and Discussion:</span> The MIC found for the three complexes were 7.8 <span style="font-family: Symbol;"><span style="font-family: Symbol;">u</span></span>g/mL. The MIC values of all the complexes are of the same order than that of ethambutol (MIC = 5.62 ug/mL), an antimycobacterial agent in clinical use. <span style="font-weight: bold;">Conclusion: </span>Further studies should include the effect against drug-resistant strains and bacilli in a state of latency, as well as the intracellular evaluation of the new complexes.<br><br><span style="font-weight: bold;">Acknowledgements: </span>This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo <span style="font-weight: bold;">(FAPESP)</span> ref. Process: 2008/10390-2 and 2009/06499-1 and <span style="font-weight: bold;">CYTED-RIIDFCM</span>.<br>      </div>
</font></p><br><b>Palavras-chave: </b>&nbsp;New Drugs, Anti-Mycobacterium tuberculosis, Copper Complexes, Quinoxaline, Alanina</td></tr></table></tr></td></table></body></html>